Top Asthma Articles for September 2012

Here are my suggestions for some of the top articles about asthma for September 2012:

Developing new asthma metrics: Rescue Index (RI) and Asthma Control Index (ACI) http://goo.gl/9L1tr

Nitric oxide (NO) is now considered an important biomarker for respiratory disease - 2012 review http://goo.gl/645wV

High pollen counts tied to ER visits for asthma | Reuters http://goo.gl/otggR

Galectin-10, a Potential Biomarker of Eosinophilic Airway Inflammation http://goo.gl/BcT2k

The co-occurrence of asthma and depression is a universal phenomenon (study) http://bit.ly/TAV4xu

Severe asthma: future treatments - 2012 full text update - Clinical & Experimental Allergy http://bit.ly/TIIiNf

"GSK drug halves attacks in hard-to-treat asthma" - anti-IL5 antibody mepolizumab for eosinophilic asthma http://goo.gl/Be6IU

30% of new prescriptions never get filled. Will smart pills boost drug compliance? http://goo.gl/omhjJ

Stopping the LABA in asthma controlled with ICS/LABA therapy results in increased asthma-associated impairment http://goo.gl/izDRe

Risk factors and characteristics of respiratory and allergic phenotypes in early childhood http://goo.gl/RWO4S

A common local adverse effect of ICS therapy for asthma is dysphonia: affects 5% to 58% of patients http://goo.gl/JoW0n

Comparison of Physician-, Biomarker (FeNO)-, Symptom-Based Adjustment of ICS in Adults With Asthma: No Difference http://buff.ly/SerAlH

Three Approaches "Equal" for Asthma Med Adjustment - Yet, there was almost double the treatment failure rate http://goo.gl/Ix9XO

The articles were selected from my Twitter stream @Allergy and Google Reader RSS subscriptions. Some of the top allergy accounts on Twitter contributed links. I appreciate the curation provided by @JuanCIvancevich @AllergyNet @IgECPD4 @DrAnneEllis @AACMaven @AllergieVoeding @allergistmommy @mrathkopf @wheezemd.

Please feel free to send suggestions for articles to allergycases@gmail.com and you will receive acknowledgement in the next edition of this publication.

No comments:

Post a Comment